Finally, the establishment of new therapeutic approaches for heart failure treatment could be an achievable goal since mTOR inhibitors like rapamycin have been described to increase cardiac function and survival in lamin A/C-deficient DCM mice by inhibiting mTORC1 signaling and lowering progerin levels in cell culture [33, 34]. The gene discussed is MTOR; the disease is familial dilated cardiomyopathy.